{"id":"W2737219695","doi":"10.1200/jco.2018.36.6_suppl.tps527","title":"S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"","keywords":"Medicine; Atezolizumab; Cystectomy; Bladder cancer; Clinical endpoint; Oncology; Internal medicine; Population; Immunotherapy; Cancer; Urology; Pembrolizumab; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001653107,0.001546839,0.001274928,0.0004287593,0.0002512397,0.0008402946,0.0009947716,0.001840208,0.007545256],"category_scores_gemma":[0.0007776786,0.0004462337,0.001237348,0.0003298331,0.0006747845,0.0005469363,0.0004271556,0.002590559,0.002005411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006267282,"about_ca_system_score_gemma":0.001424849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006711227,"about_ca_topic_score_gemma":0.001637382,"domain_scores_codex":[0.9996783,0.0001519456,0.00001925298,0.00004209265,0.00003423884,0.00007422412],"domain_scores_gemma":[0.9995527,0.00005801701,0.0001001246,0.00003365807,0.00002835119,0.000227201],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7283266,0.04029058,0.005900396,0.002787035,0.001405317,0.0004681305,0.0002578116,0.003351096,0.04325588,0.001079474,0.0135395,0.1593382],"study_design_scores_gemma":[0.7684582,0.2186436,0.004974677,0.00008752646,0.0002558736,0.000317376,0.0000356211,0.001324042,0.002209096,0.0002716883,0.003400667,0.00002163467],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785603,0.003683865,0.000891358,0.001083742,0.0004093671,0.004682044,0.003711136,0.0003582381,0.006620123],"genre_scores_gemma":[0.9644444,0.00247909,0.002583512,0.003018021,0.0003035243,0.005209968,0.01098745,0.00006339327,0.01091076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007545256,"threshold_uncertainty_score":0.02524143,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.169627356306863,"score_gpt":0.5273361999820035,"score_spread":0.3577088436751406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}